查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1676692

mRNA 合成與製造市場：按服務、按服務類型、按製造流程、按製造規模、按技術、按應用、按用途、按最終用戶 - 2025 年至 2030 年全球預測

mRNA Synthesis & Manufacturing Market by Services, Service Type, Manufacturing Process, Manufacturing Scale, Technology, Application, Usage, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

mRNA 合成和製造市場預計在 2023 年價值為 24.8 億美元，2024 年為 27.1 億美元，到 2030 年達到 46.5 億美元，複合年成長率為 9.35%。

主要市場統計數據
基準年 2023 年 24.8億美元
預計 2024 年 27.1億美元
預測年份 2030 46.5億美元
複合年成長率（%） 9.35％

mRNA 合成和製造已成為生物技術領域的變革性技術，推動創新並重新定義治療藥物和疫苗開發。最近的全球健康挑戰加速了對高效、可擴展、高品質 mRNA 生產的需求。如此動態的環境要求對塑造未來的核心流程、市場促進因素和策略舉措有細緻的了解。

mRNA 生產領域的特點是技術進步迅速和法律規範不斷發展。 mRNA 封端、配方、試管內轉錄和精製方面的新技術不僅提高了生產速度和質量，而且還制定了新的行業標準。隨著市場的擴大，相關人員越來越面臨有關流程選擇、技術適應和資源分配的複雜決策。

從研究機構到大型製藥企業，產業相關人員都在投資下一代製造能力，以保持競爭優勢。先進的酵素加帽和加帽模擬方法的結合，加上儲存和配送物流的進步，簡化了客戶特異性和標準化 mRNA 產品的交付。本入門書說明探討了影響 mRNA 合成和製造市場的各種因素，為進一步分析和策略規劃提供了框架。

改變 mRNA 合成與製造市場

mRNA 合成和製造業正在經歷一場變革性轉變，重新定義傳統範式並為創新成長鋪平道路。在前所未有的全球需求的推動下，老字型大小企業和新興企業都在採用技術改進和新方法來抓住新機會。

基因工程和密碼子最佳化的快速進步導致了試管內轉錄過程的顯著改善。整合的自動化工作流程不僅縮短了生產時間，還提高了可擴展性和可重複性，這是解決緊急醫療保健需求的關鍵因素。此外，在公共衛生危機的緊迫性推動下，不斷發展的法規正在加速新製造技術的採用，從而縮短核准週期並提高品管的透明度。

透過對先進的脂質奈米顆粒 (LNP) 配方和酵素封端技術的大力投資，這種轉型正在進一步擴大。這些方法的綜合發展為解決治療和疫苗應用提供了強力的框架。此外，面對複雜的全球供應鏈挑戰，加強儲存和分銷物流對於確保高品質的 mRNA 產品有效進入目標市場至關重要。

當今市場的特點是自訂並向特定客戶需求轉變。根據客戶特定訂單和研究規範客製化的mRNA 合成現已與專注於目錄或現成 mRNA 選擇的傳統方法相媲美。這一演變反映了該行業致力於滿足從實驗研究到大規模臨床應用的多樣化需求。本質上，這些市場轉變強調了從傳統的大規模生產轉向更靈活、更具適應性、更精準的製造生態系統的轉變。

mRNA 製造中的關鍵細分見解

仔細觀察 mRNA 合成和製造市場細分，可以發現滿足特定要求和應用領域的多個方面。從服務角度分析市場，封端和尾端、配方、電腦設計、修改和最佳化、精製和品管、儲存和分銷以及模板 DNA 製備等研究為理解技術複雜性提供了基本框架。此外，考慮到服務類型的差異，市場可以評估客自訂mRNA 合成和標準 mRNA 製造。前者與客戶特定的 mRNA 訂單和客製化研究規範密切相關，而後者包括分類的 mRNA 變異和現成的 mRNA 選擇，反映了多樣化的營運模式。

基於製造流程的細分分析重點在於先進的LNP製劑技術、與帽類似物結合的酵素加帽技術、與密碼子最佳化相結合的基因工程技術，以及體外轉錄技術、使用質體DNA模板、多聚腺苷酸化和RNA精製等創新技術。這種觀點抓住了區分產品和影響其市場定位的關鍵技術和工藝因素。同樣重要的是基於生產規模的細分，突顯商業、實驗室和中試規模營運的現實和挑戰，每個規模都呈現出各自獨特的營運框架和經濟影響。

基於技術的細分引入了體外合成與體內合成的二分法，每種方法都代表一種具有其自身優點和局限性的專門技術方法。基於應用的細分進一步將市場分類為治療學和疫苗學。治療領域主要集中在腫瘤學、感染疾病和罕見疾病，呈現出臨床需求和創新解決方案之間的複雜交互作用。同時，疫苗領域正在向預防性疫苗和治療性疫苗多元化發展，強調預防和治療之間的策略性平衡。

應用程式和最終用戶細分等其他方面提供了對市場動態的細緻洞察。在用途方面，區分人類用途和獸醫用途，反映了有針對性的產品設計和性能標準。同時，透過繪製學術研究機構、受託製造廠商和製藥及生物技術公司之間的相互關係來明確最終用戶的細分，並在學術界內部根據政府研究機構和大學實驗室進一步進行區分。這種層次化的細分凸顯了市場的多面性，並為滿足不同客戶群的精確需求的客製化策略和有針對性的產品創新提供了藍圖。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球感染疾病疫情不斷增加
      • 生技公司與教育機構的夥伴關係
    • 限制因素
      • 與 mRNA 相關的複雜且昂貴的製造過程
    • 機會
      • 癌症治療中的新型 mRNA 應用
      • 整合資料分析和人工智慧以增強 mRNA 序列設計和最佳化
      • 來自政府和私人實體的大量資金和投資
    • 任務
      • 與 mRNA 合成和製造相關的倫理問題
      • 應對複雜的 mRNA 調控環境的挑戰
  • 市場區隔分析
    • 服務：擴大使用校正和最佳化服務，以提高穩定性和翻譯效率。
    • 服務類型：提供個人化解決方案，利用客自訂mRNA 合成吸引生技新興企業和研究機構
    • 製造流程：廣泛採用基因工程和密碼子最佳化工藝，以最大限度提高蛋白質產量並確保最佳基因表現
    • 生產規模：成長中的製藥公司和成熟的生物技術公司正在加大商業規模生產
    • 技術：由於生產週期短、合成製程控制水準高，體外合成的採用正在增加。
    • 應用：擴大 mRNA 合成和製造在疫苗中的作用
    • 用途：對基於人類 mRNA 的療法和疫苗的需求日益成長
    • 最終用戶：製藥和生物技術公司正在大力投資 mRNA 技術，因為它在開發疫苗和治療方法方面具有潛力。
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 mRNA 合成與製造市場（按服務）

  • 封蓋和拖尾
  • 處方
  • In Silico設計
  • 修復和最佳化
  • 精製和品管
  • 儲存和運輸
  • 模板 DNA 的製備

第7章 mRNA 合成與製造市場（依服務類型）

  • 自訂mRNA 合成
    • 客戶特定的 mRNA 訂單
    • 客製化調查規範
  • 標準 mRNA 生產
    • 已編目的 mRNA 變異體
    • 現成的 mRNA 選擇

第 8 章 mRNA 合成與製造市場（依製造流程）

  • 先進的LNP配方技術
  • 酵素加帽和加帽類似物
  • 基因工程和密碼子最佳化
  • 體外轉錄
  • 質體DNA模板
  • 多聚腺苷酸化
  • RNA精製技術

第9章 mRNA 合成和製造市場（按製造規模）

  • 商業規模
  • 實驗室規模
  • 中試規模

第 10 章 mRNA 合成與製造市場（按技術）

  • 體外合成
  • 體內合成

第 11 章 mRNA 合成與製造市場（按應用）

  • 治療
    • 癌症
    • 感染疾病
    • 罕見疾病
  • 疫苗
    • 預防疫苗
    • 治療性疫苗

第 12 章 mRNA 合成與製造市場（按應用）

  • 人類使用
  • 獸醫用途

第 13 章 mRNA 合成與製造市場（按最終用戶分類）

  • 學術研究所
    • 政府研究機構
    • 大學實驗室
  • 契約製造組織
  • 製藥和生物技術公司

第 14 章美洲 mRNA 合成與製造市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

15. 亞太地區 mRNA 合成與製造市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

16. 歐洲、中東和非洲 mRNA 合成和製造市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第17章 競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited
  • Bio-Synthesis Inc.
  • Creative Biogene
  • Creative Biolabs
  • Croyez Bioscience Co., Ltd.
  • Danaher Corporation
  • FUJIFILM Wako Pure Chemical Corporation
  • Genewiz by Azenta Life Sciences
  • GenScript Biotech Corporation
  • Jena Bioscience GmbH by Enzo Biochem Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • New England Biolabs, Inc.
  • PackGene Biotech, Inc.
  • Promega Corporation
  • Samsung Biologics Co., Ltd.
  • Sartorius AG
  • ST Pharm
  • System Biosciences, LLC
  • Takara Bio Inc.
  • Telesis Bio Inc.
  • Thermo Fisher Scientific Inc.
  • TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC
  • WuXi Biologics（Cayman）Inc
Product Code: MRR-6067B28994B1

The mRNA Synthesis & Manufacturing Market was valued at USD 2.48 billion in 2023 and is projected to grow to USD 2.71 billion in 2024, with a CAGR of 9.35%, reaching USD 4.65 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 2.48 billion
Estimated Year [2024] USD 2.71 billion
Forecast Year [2030] USD 4.65 billion
CAGR (%) 9.35%

mRNA synthesis and manufacturing have emerged as transformative technologies in the biotechnology sector, driving innovation and redefining therapeutic and vaccine development. In the wake of recent global health challenges, the demand for efficient, scalable, and high-quality mRNA production has accelerated. This dynamic environment calls for a nuanced understanding of the core processes, market drivers, and strategic initiatives that are shaping the future.

The landscape of mRNA production is marked by rapid technological advancements and evolving regulatory frameworks. Novel techniques in mRNA capping, formulation, in vitro transcription, and purification are not only enhancing the speed and quality of production but are also setting new industry standards. As the market expands, stakeholders are increasingly confronted with complex decisions regarding process selection, technology adaptation, and resource allocation.

Industry participants-from research institutes to major pharmaceutical corporations-are investing in next-generation manufacturing capabilities to maintain competitive advantage. The integration of advanced enzymatic capping and cap analogue methodologies, combined with the evolution of storage and distribution logistics, is streamlining the delivery of both client-specific and standardized mRNA products. This introductory section sets the stage for an in-depth exploration of the various elements that influence the mRNA synthesis and manufacturing market, providing a framework for further analysis and strategic planning.

Transformative Shifts in the mRNA Synthesis & Manufacturing Landscape

The mRNA synthesis and manufacturing industry is witnessing transformative shifts that are redefining traditional paradigms and paving the way for innovative growth. Established companies and emerging players alike are embracing technological enhancements and novel approaches to seize new opportunities, driven by unprecedented global demand.

Rapid advancements in genetic engineering and codon optimization have led to significant improvements in in vitro transcription processes. The integration of automated workflows has not only reduced production timelines but has also increased scalability and reproducibility-critical factors in responding to urgent healthcare needs. Moreover, regulatory evolutions, driven by the urgency of public health crises, have accelerated the adoption of new manufacturing technologies, enabling faster approval cycles and enhanced transparency in quality control.

These transformative shifts are amplified by rigorous investments in advanced lipid nanoparticle (LNP) formulation and enzymatic capping technologies. The combined evolution of these methodologies offers a robust framework for addressing both therapeutic and vaccine applications. Additionally, enhancements in storage and distribution logistics have been pivotal in ensuring that high-quality mRNA products reach their intended markets efficiently, even in the face of complex global supply chain challenges.

The market today is defined by a shift towards customization and specific client requirements. Custom mRNA synthesis, driven by client-specific orders and tailored research specifications, now stands shoulder-to-shoulder with conventional approaches that focus on cataloged or off-the-shelf mRNA selections. This evolution reflects the industry's commitment to meeting diverse demands, ranging from experimental research to large-scale clinical applications. In essence, these market shifts underscore a transition from conventional mass production to a more agile, adaptable, and precision-focused manufacturing ecosystem.

Key Segmentation Insights in mRNA Manufacture

A detailed examination of market segmentation in mRNA synthesis and manufacturing reveals multiple dimensions that cater to specific requirements and application domains. Analyzing the market from the perspective of services, the study of capping and tailing, formulation, in silico design, modification and optimization, purification and quality control, storage and distribution, and template DNA preparation provide a foundational framework for understanding technological intricacies. Moreover, when considering service type distinctions, the market is evaluative of both custom mRNA synthesis and standard mRNA production. The former is intricately linked to client-specific mRNA orders and tailored research specifications, while the latter encompasses cataloged mRNA variants and off-the-shelf mRNA selections, reflecting diverse operational models.

The segmentation analysis based on the manufacturing process highlights innovations such as advanced LNP formulation technology, enzymatic capping combined with cap analogues, genetic engineering with codon optimization, as well as in vitro transcription techniques, plasmid DNA template use, polyadenylation, and RNA purification. This perspective captures the critical technological and process-driven factors that differentiate products and influence market positioning. Equally important is the segmentation based on manufacturing scale, which concentrates on the practicalities and challenges of commercial scale, lab scale, and pilot scale operations, each presenting unique operational frameworks and economic implications.

Further segmentation based on technology introduces the dichotomy between in vitro synthesis and in vivo synthesis, each representing specialized technological approaches with their own advantages and limitations. Application-based segmentation further dissects the market into therapeutics and vaccines. Here, the therapeutic segment, with its focus on cancer, infectious diseases, and rare diseases, demonstrates a complex interplay of clinical requirements and innovative solutions. Meanwhile, the vaccine segment diversifies into prophylactic vaccines and therapeutic vaccines, highlighting a strategic balance between prevention and treatment.

Additional dimensions such as usage and end-user segmentation offer nuanced insights into market dynamics. The usage perspective distinguishes between human and veterinary use, reflecting targeted product design and performance criteria. Meanwhile, end-user segmentation provides clarity by mapping the interrelationships between academic and research institutes, contract manufacturing organizations, and pharmaceutical and biotechnology companies, with further differentiation within academic and research institutes based on government research bodies and university laboratories. This layered segmentation highlights the multifaceted nature of the market, offering a roadmap for tailored strategies and targeted product innovations that meet the precise needs of different customer segments.

Based on Services, market is studied across Capping & Tailing, Formulation, In Silico Design, Modification & Optimization, Purification & Quality Control, Storage & Distribution, and Template DNA Preparation.

Based on Service Type, market is studied across Custom mRNA Synthesis and Standard mRNA Production. The Custom mRNA Synthesis is further studied across Client-Specific mRNA Orders and Tailored Research Specifications. The Standard mRNA Production is further studied across Cataloged mRNA Variants and Off-the-Shelf mRNA Selections.

Based on Manufacturing Process, market is studied across Advanced LNP Formulation Technology, Enzymatic Capping & Cap Analogues, Genetic Engineering & Codon Optimization, In Vitro Transcription, Plasmid DNA Template, Polyadenylation, and RNA Purification Techniques.

Based on Manufacturing Scale, market is studied across Commercial Scale, Lab Scale, and Pilot Scale.

Based on Technology, market is studied across In Vitro Synthesis and In Vivo Synthesis.

Based on Application, market is studied across Therapeutics and Vaccines. The Therapeutics is further studied across Cancer, Infectious Diseases, and Rare Diseases. The Vaccines is further studied across Prophylactic Vaccines and Therapeutic Vaccines.

Based on Usage, market is studied across Human Use and Veterinary Use.

Based on End-User, market is studied across Academic & Research Institutes, Contract Manufacturing Organizations, and Pharmaceutical & Biotechnology Companies. The Academic & Research Institutes is further studied across Government Research Bodies and University Laboratories.

Key Regional Insights Influencing Market Dynamics

The geographic dimension of mRNA synthesis and manufacturing is characterized by varied regional trends and strategic imperatives. Analysis across the Americas has revealed robust investment in state-of-the-art research and development facilities, driven by both private and public funding that positions the region at the forefront of technological innovation. This dynamic is propelled by strong collaborations between academic institutions and the pharmaceutical industry, fostering an ecosystem conducive to rapid product iteration and market responsiveness.

Turning to the Europe, Middle East & Africa region, the focus is on regulatory harmonization and quality control standards that are essential for both local markets and broader international trade. Increased governmental support paired with strategic partnerships in biotech research has enabled significant inroads in mRNA technology. This region's evolved regulatory framework not only supports innovative research but also accelerates the path from laboratory discovery to clinical application, thereby enhancing overall market competitiveness.

In the Asia-Pacific region, the market is buoyed by rapid industrial growth, extensive investments in manufacturing infrastructure, and a burgeoning talent pool of scientific professionals. Innovations here are underscored by a commitment to scale commercial production while maintaining rigorous standards in laboratory research. The integration of advanced manufacturing processes with local expertise supports both customized and standardized production models, driving efficiency and ensuring that emerging products meet global quality benchmarks. Together, these regional insights play a pivotal role in shaping market strategies and investment decisions for companies operating across diverse geographies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Shaping Industry Innovation

The competitive landscape is defined by the presence of several key companies that continuously drive innovation and market growth in mRNA synthesis and manufacturing. Leading firms such as Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited and Bio-Synthesis Inc. have been instrumental in advancing client-specific service offerings, leveraging their robust research capabilities to meet specialized demands. Creative Biogene and Creative Biolabs contribute significantly by combining tailored research with comprehensive standard production platforms, thereby bridging the gap between novelty and consistency.

Another critical group includes Croyez Bioscience Co., Ltd. and Danaher Corporation, both of which invest heavily in state-of-the-art production technologies that improve process automation and yield. FUJIFILM Wako Pure Chemical Corporation and Genewiz by Azenta Life Sciences focus on providing high-quality enzymes and reagents that are essential to enhancing the precision and robustness of mRNA manufacturing. GenScript Biotech Corporation and Jena Bioscience GmbH by Enzo Biochem Inc. continue to influence the market through their dedicated advancements in process optimization and genetic engineering techniques.

The manufacturing scale is further impacted by major industry leaders such as Lonza Group Ltd. and Merck KGaA, which have set benchmarks in large-scale production workflows as well as quality control mechanisms. New England Biolabs, Inc., alongside PackGene Biotech, Inc. and Promega Corporation, are well-regarded for their contributions to developing efficient pilot and lab scale production systems while maintaining consistency across commercial scale outputs. Companies like Samsung Biologics Co., Ltd. and Sartorius AG have also brought precision and operational excellence to the forefront, expanding production capacities and streamlining logistics.

Additional market influencers include ST Pharm and System Biosciences, LLC, who invest in cutting-edge research and process innovation. Takara Bio Inc. and Telesis Bio Inc. further add to the competitive momentum by focusing on integrated manufacturing solutions that blend in vitro synthesis with advanced analytic capabilities. Thermo Fisher Scientific Inc. and TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC, with their diverse service portfolios, have also positioned themselves as leaders in both custom and standard mRNA production methodologies. Finally, WuXi Biologics (Cayman) Inc. rounds out an impressive list of companies dedicated to advancing production capabilities, reinforcing the industry's commitment to quality and innovation at every stage of mRNA synthesis and manufacturing.

The report delves into recent significant developments in the mRNA Synthesis & Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited, Bio-Synthesis Inc., Creative Biogene, Creative Biolabs, Croyez Bioscience Co., Ltd., Danaher Corporation, FUJIFILM Wako Pure Chemical Corporation, Genewiz by Azenta Life Sciences, GenScript Biotech Corporation, Jena Bioscience GmbH by Enzo Biochem Inc., Lonza Group Ltd., Merck KGaA, New England Biolabs, Inc., PackGene Biotech, Inc., Promega Corporation, Samsung Biologics Co., Ltd., Sartorius AG, ST Pharm, System Biosciences, LLC, Takara Bio Inc., Telesis Bio Inc., Thermo Fisher Scientific Inc., TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC, and WuXi Biologics (Cayman) Inc. Actionable Recommendations for Industry Leaders in mRNA Manufacturing

In the face of rapid technological evolution and competitive market forces, industry leaders must adopt proactive strategies to maintain and enhance their market positioning. To thrive in this environment, companies should consider the following actionable recommendations:

Invest in Continuous Process Optimization: The rapid pace of technological advancements demands ongoing investments in process innovation. Establish dedicated research and development units to continuously refine production techniques, focusing on areas such as advanced LNP formulation technology, enzymatic capping innovations, and state-of-the-art genetic engineering practices. Regular audits of in vitro transcription, plasmid template preparation, and RNA purification technologies will not only drive operational efficiencies but also ensure compliance with emerging regulatory standards.

Embrace Flexible Production Models: With the market segmented by manufacturing scale-from lab and pilot scale to full commercial production-it is crucial to build adaptive production units that can scale based on demand fluctuations. Flexible manufacturing setups allow firms to optimize resource allocation and manage risks associated with overproduction or underutilization of facilities. Adopting modular manufacturing strategies can help streamline transitions between different production scales, ensuring a seamless response to shifting market dynamics.

Strengthen Collaborative Networks: In today's competitive landscape, forging strategic partnerships is key to unlocking synergies and driving innovation. Collaborations with academic research institutions, government research bodies, and private sector leaders can facilitate the exchange of expertise and best practices. Such networks not only enhance technological capabilities but also provide opportunities for joint research initiatives, faster adoption of breakthrough technologies, and improved market outreach.

Prioritize Technology Integration: With segmentation based on service type and technological approaches-whether in vitro or in vivo synthesis-integrating advanced analytics and process automation is critical. Utilize digital twin technology and real-time data monitoring systems to optimize manufacturing workflows, improve quality control, and reduce production bottlenecks. Embracing Industry 4.0 principles will enable organizations to unlock efficiencies and make data-driven decisions that enhance overall operational performance.

Diversify Product Portfolios: Expanding product offerings to include both custom mRNA synthesis and standardized production allows companies to serve a broader segment of the market. By tailoring solutions to meet specific client needs-whether for client-specific orders or cataloged mRNA variants-businesses can capture a wider audience while mitigating risks associated with relying on a single product line. Diversification also opens up new revenue streams, enhances market resilience, and fosters a customer-centric approach to product development.

Focus on Regulatory Compliance and Quality Assurance: Given the critical impact of quality control in mRNA manufacturing, robust systems to ensure regulatory compliance are indispensable. Regular training, process audits, and investments in advanced quality control technologies will minimize risks and build consumer trust. Establishing transparent and rigorous documentation practices is essential for navigating regulatory landscapes and sustaining long-term market viability.

Invest in Workforce Development: As technological complexity increases, so does the need for skilled personnel. Industry leaders should prioritize training and development programs to equip their workforce with the latest techniques in mRNA synthesis and manufacturing. Enhancing technical expertise not only improves operational efficiency but also drives innovation, ensuring that companies remain agile in the face of emerging industry trends.

Pursue Market Expansion Strategically: Finally, a thorough understanding of regional market dynamics-across the Americas, Europe, Middle East & Africa, and Asia-Pacific-should inform expansion strategies. Tailoring market entry plans and product offerings to the unique demands and regulatory environments of each region can unlock new opportunities and bolster international growth. Overall, strategic investments in process innovation, talent development, and robust quality assurance practices will position industry leaders for sustainable success in a competitive and rapidly evolving market.

Conclusion: Embracing Innovation for Future Growth

The mRNA synthesis and manufacturing landscape is characterized by rapid innovation, complex segmentation, and expansive market opportunities. As industry leaders continue to leverage advanced manufacturing processes, integrate cutting-edge technology solutions, and foster strategic collaborations, the stage is set for a new era of precision medicine and breakthrough therapeutic solutions.

This comprehensive analysis underscores the importance of continuous process optimization, flexible production models, and the integration of state-of-the-art technologies. The segmentation insights reveal a market that is as diverse in its applications as it is in its methodologies. Whether it is the intricate processes involved in enzymatic capping, the precision of genetic engineering, or the adaptability required for various manufacturing scales, each facet contributes to a vibrant and competitive ecosystem.

Moreover, regional insights highlight that global collaboration and tailored strategies are pivotal to navigating the unique challenges and opportunities present in different geographies. With major players driving innovation and setting high benchmarks for quality and efficiency, the future of mRNA synthesis and manufacturing looks not only promising but fundamentally transformative.

In conclusion, by embracing a culture of innovation, proactive market expansion, and continuous improvement, stakeholders can unlock unprecedented growth and revolutionize the manner in which life-saving therapies and vaccines are developed. The journey ahead calls for a steadfast commitment to quality, agility, and visionary leadership, ensuring that the full potential of mRNA technology is realized in both current and future applications.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of infectious diseases across the globe
      • 5.1.1.2. Partnerships between biotech firms and educational institutions
    • 5.1.2. Restraints
      • 5.1.2.1. Complex and costly manufacturing processes associated with mRNA
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging mRNA applications in cancer therapeutics
      • 5.1.3.2. Integrating data analytics and AI to enhance mRNA sequence design and optimization
      • 5.1.3.3. Significant funding and investment from governments and private entities
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical concerns associated with mRNA synthesis & manufacturing
      • 5.1.4.2. Diificulties in navigating the complex regulatory landscape for mRNA
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Services: Increasing usage of the modification & optimization services focuses on enhancing stability and translational efficiency
    • 5.2.2. Service Type: Significant custom mRNA synthesis utilization in delivering personalized solutions, attracting biotech startups and research institutions
    • 5.2.3. Manufacturing Process: Substantial adoption of genetic engineering & codon optimization process for maximizing protein yield and ensuring optimal gene expression
    • 5.2.4. Manufacturing Scale: Increased commercial scale production driven by growing pharmaceutical companies and established biotech firms
    • 5.2.5. Technology: Rising adoption of in vitro synthesis due to its rapid production cycle and the control level offered over the synthesis process
    • 5.2.6. Application: Expanding role of mRNA synthesis & manufacturing for the vaccines
    • 5.2.7. Usage: Evolving need for mRNA-based therapeutics and vaccines for humans usage
    • 5.2.8. End-User: Pharmaceutical & biotechnology companies are heavily invested in mRNA technology for its potential in vaccine and therapeutic development
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. mRNA Synthesis & Manufacturing Market, by Services

  • 6.1. Introduction
  • 6.2. Capping & Tailing
  • 6.3. Formulation
  • 6.4. In Silico Design
  • 6.5. Modification & Optimization
  • 6.6. Purification & Quality Control
  • 6.7. Storage & Distribution
  • 6.8. Template DNA Preparation

7. mRNA Synthesis & Manufacturing Market, by Service Type

  • 7.1. Introduction
  • 7.2. Custom mRNA Synthesis
    • 7.2.1. Client-Specific mRNA Orders
    • 7.2.2. Tailored Research Specifications
  • 7.3. Standard mRNA Production
    • 7.3.1. Cataloged mRNA Variants
    • 7.3.2. Off-the-Shelf mRNA Selections

8. mRNA Synthesis & Manufacturing Market, by Manufacturing Process

  • 8.1. Introduction
  • 8.2. Advanced LNP Formulation Technology
  • 8.3. Enzymatic Capping & Cap Analogues
  • 8.4. Genetic Engineering & Codon Optimization
  • 8.5. In Vitro Transcription
  • 8.6. Plasmid DNA Template
  • 8.7. Polyadenylation
  • 8.8. RNA Purification Techniques

9. mRNA Synthesis & Manufacturing Market, by Manufacturing Scale

  • 9.1. Introduction
  • 9.2. Commercial Scale
  • 9.3. Lab Scale
  • 9.4. Pilot Scale

10. mRNA Synthesis & Manufacturing Market, by Technology

  • 10.1. Introduction
  • 10.2. In Vitro Synthesis
  • 10.3. In Vivo Synthesis

11. mRNA Synthesis & Manufacturing Market, by Application

  • 11.1. Introduction
  • 11.2. Therapeutics
    • 11.2.1. Cancer
    • 11.2.2. Infectious Diseases
    • 11.2.3. Rare Diseases
  • 11.3. Vaccines
    • 11.3.1. Prophylactic Vaccines
    • 11.3.2. Therapeutic Vaccines

12. mRNA Synthesis & Manufacturing Market, by Usage

  • 12.1. Introduction
  • 12.2. Human Use
  • 12.3. Veterinary Use

13. mRNA Synthesis & Manufacturing Market, by End-User

  • 13.1. Introduction
  • 13.2. Academic & Research Institutes
    • 13.2.1. Government Research Bodies
    • 13.2.2. University Laboratories
  • 13.3. Contract Manufacturing Organizations
  • 13.4. Pharmaceutical & Biotechnology Companies

14. Americas mRNA Synthesis & Manufacturing Market

  • 14.1. Introduction
  • 14.2. Argentina
  • 14.3. Brazil
  • 14.4. Canada
  • 14.5. Mexico
  • 14.6. United States

15. Asia-Pacific mRNA Synthesis & Manufacturing Market

  • 15.1. Introduction
  • 15.2. Australia
  • 15.3. China
  • 15.4. India
  • 15.5. Indonesia
  • 15.6. Japan
  • 15.7. Malaysia
  • 15.8. Philippines
  • 15.9. Singapore
  • 15.10. South Korea
  • 15.11. Taiwan
  • 15.12. Thailand
  • 15.13. Vietnam

16. Europe, Middle East & Africa mRNA Synthesis & Manufacturing Market

  • 16.1. Introduction
  • 16.2. Denmark
  • 16.3. Egypt
  • 16.4. Finland
  • 16.5. France
  • 16.6. Germany
  • 16.7. Israel
  • 16.8. Italy
  • 16.9. Netherlands
  • 16.10. Nigeria
  • 16.11. Norway
  • 16.12. Poland
  • 16.13. Qatar
  • 16.14. Russia
  • 16.15. Saudi Arabia
  • 16.16. South Africa
  • 16.17. Spain
  • 16.18. Sweden
  • 16.19. Switzerland
  • 16.20. Turkey
  • 16.21. United Arab Emirates
  • 16.22. United Kingdom

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2023
  • 17.2. FPNV Positioning Matrix, 2023
  • 17.3. Competitive Scenario Analysis
    • 17.3.1. TriLink and Alphazyme's CleanScribe RNA Polymerase revolutionizes mRNA synthesis with reduced dsRNA formation
    • 17.3.2. Partnership between Telesis Bio and Beckman Coulter Life Sciences transforms DNA and mRNA synthesis through scalable and high-fidelity biofoundries
    • 17.3.3. Strategic partnership in mRNA synthesis, Primrose Bio, and ExPLoRNA transform therapeutic advancements through innovation
    • 17.3.4. Strategic acquisition of echelon biosciences by VION biosciences to increase mRNA therapies and life science offerings
    • 17.3.5. GSK collaborates with Touchlight to revolutionize mRNA vaccine production using advanced dbDNA technology
    • 17.3.6. Applied DNA secures patent for innovative Linea IVT technology advancing mRNA synthesis efficiency
    • 17.3.7. WACKER unveils mRNA competence center in Germany to expand global pandemic preparedness and biotech innovation
    • 17.3.8. Takara Bio launched genetically enhanced PrimeCap T7 RNA polymerase, revolutionizing safe mRNA synthesis for advanced therapeutics
    • 17.3.9. TriLink BioTechnologies Expands Late-Phase mRNA Drug Manufacturing with New San Diego Facility
    • 17.3.10. Strategic alliance between PackGene Biotech and Kudo Biotechnology transforms global mRNA manufacturing landscape with comprehensive end-to-end solutions
  • 17.4. Strategy Analysis & Recommendation
    • 17.4.1. GenScript Biotech Corporation
    • 17.4.2. Thermo Fisher Scientific Inc.
    • 17.4.3. Samsung Biologics Co., Ltd.
    • 17.4.4. Danaher Corporation

Companies Mentioned

  • 1. Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited
  • 2. Bio-Synthesis Inc.
  • 3. Creative Biogene
  • 4. Creative Biolabs
  • 5. Croyez Bioscience Co., Ltd.
  • 6. Danaher Corporation
  • 7. FUJIFILM Wako Pure Chemical Corporation
  • 8. Genewiz by Azenta Life Sciences
  • 9. GenScript Biotech Corporation
  • 10. Jena Bioscience GmbH by Enzo Biochem Inc.
  • 11. Lonza Group Ltd.
  • 12. Merck KGaA
  • 13. New England Biolabs, Inc.
  • 14. PackGene Biotech, Inc.
  • 15. Promega Corporation
  • 16. Samsung Biologics Co., Ltd.
  • 17. Sartorius AG
  • 18. ST Pharm
  • 19. System Biosciences, LLC
  • 20. Takara Bio Inc.
  • 21. Telesis Bio Inc.
  • 22. Thermo Fisher Scientific Inc.
  • 23. TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC
  • 24. WuXi Biologics (Cayman) Inc

LIST OF FIGURES

  • FIGURE 1. MRNA SYNTHESIS & MANUFACTURING MARKET MULTI-CURRENCY
  • FIGURE 2. MRNA SYNTHESIS & MANUFACTURING MARKET MULTI-LANGUAGE
  • FIGURE 3. MRNA SYNTHESIS & MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 4. MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 23. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 27. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 31. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 32. MRNA SYNTHESIS & MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 33. MRNA SYNTHESIS & MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MRNA SYNTHESIS & MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MRNA SYNTHESIS & MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CAPPING & TAILING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN SILICO DESIGN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MODIFICATION & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PURIFICATION & QUALITY CONTROL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STORAGE & DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TEMPLATE DNA PREPARATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CLIENT-SPECIFIC MRNA ORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TAILORED RESEARCH SPECIFICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CATALOGED MRNA VARIANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY OFF-THE-SHELF MRNA SELECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ADVANCED LNP FORMULATION TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ENZYMATIC CAPPING & CAP ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GENETIC ENGINEERING & CODON OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO TRANSCRIPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PLASMID DNA TEMPLATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY POLYADENYLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RNA PURIFICATION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY LAB SCALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PILOT SCALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VIVO SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY HUMAN USE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VETERINARY USE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GOVERNMENT RESEARCH BODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY UNIVERSITY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 96. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 97. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 109. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 110. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 118. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 121. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 122. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 123. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 134. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 135. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 136. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 156. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 158. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 162. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 164. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 169. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 170. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 171. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 172. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 175. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 176. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 177. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 180. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 182. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 183. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 184. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 185. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 188. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 189. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 190. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 192. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 193. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 195. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 196. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 197. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 198. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 201. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 202. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 203. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 205. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 206. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 208. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 209. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 210. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 211. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 212. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 214. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 215. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 216. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 218. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 219. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 221. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 222. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 223. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 224. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 227. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 228. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 229. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 232. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 234. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 236. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 238. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 240. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 241. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 242. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 244. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 245. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 247. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 248. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 249. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 250. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 252. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 253. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 254. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 255. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 256. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 258. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 260. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 262. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 266. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 267. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 268. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 269. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 270. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 271. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 273. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 274. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 275. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 276. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 278. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 279. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 280. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 281. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 282. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 283. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 284. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 286. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 287. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 288. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 289. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 290. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 291. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 292. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 293. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
  • TABLE 294. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 295. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 296. VIETNAM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 297. VIETNAM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. VIETNAM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 299. VIETNAM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 300. VIETNAM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 301. VIETNAM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
  • TABLE 302. VIETNAM MRNA SYNTHESIS & MANUFACTURING MARKET